Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
View / Open Files
Authors
Blyuss, Oleg
Gaba, Faiza
Burnell, Matthew
Gan, Carmen
Taylor, Rohan
Turnbull, Clare
Legood, Rosa
Zaikin, Alexey
Menon, Usha
Jacobs, Ian
Publication Date
2018-08Journal Title
J Med Genet
ISSN
0022-2593
Publisher
BMJ
Volume
55
Issue
8
Pages
538-545
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Manchanda, R., Blyuss, O., Gaba, F., Gordeev, V. S., Jacobs, C., Burnell, M., Gan, C., et al. (2018). Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.. J Med Genet, 55 (8), 538-545. https://doi.org/10.1136/jmedgenet-2017-105195
Abstract
BACKGROUND: BRCA carrier identification offers opportunities for early diagnoses, targeted treatment and cancer prevention. We evaluate BRCA- carrier detection rates in general and Ashkenazi Jewish (AJ) populations across Greater London and estimate time-to-detection of all identifiable BRCA carriers. METHODS: BRCA carrier data from 1993 to 2014 were obtained from National Health Service genetic laboratories and compared with modelled predictions of BRCA prevalence from published literature and geographical data from UK Office for National Statistics. Proportion of BRCA carriers identified was estimated. Prediction models were developed to fit BRCA detection rate data. BRCA carrier identification rates were evaluated for an 'Angelina Jolie effect'. Maps for four Greater London regions were constructed, and their relative BRCA detection rates were compared. Models developed were used to predict future time-to-identify all detectable BRCA carriers in AJ and general populations. RESULTS: Until 2014, only 2.6% (3072/111 742 estimated) general population and 10.9% (548/4985 estimated) AJ population BRCA carriers have been identified in 16 696 608 (AJ=190 997) Greater London population. 57% general population and 54% AJ mutations were identified through cascade testing. Current detection rates mirror linear fit rather than parabolic model and will not identify all BRCA carriers. Addition of unselected ovarian/triple-negative breast cancer testing would take >250 years to identify all BRCA carriers. Doubling current detection rates can identify all 'detectable' BRCA carriers in the general population by year 2181, while parabolic and triple linear rates can identify 'detectable' BRCA carriers by 2084 and 2093, respectively. The linear fit model can identify 'detectable' AJ carriers by 2044. We did not find an Angelina Jolie effect on BRCA carrier detection rates. There was a significant difference in BRCA detection rates between geographical regions over time (P<0.001). CONCLUSIONS: The majority of BRCA carriers have not been identified, missing key opportunities for prevention/earlier diagnosis. Enhanced and new strategies/approaches are needed.
Keywords
Humans, Neoplasms, Population Surveillance, Heterozygote, Mutation, Genes, BRCA1, Genes, BRCA2, Jews, London, Female, Genetic Testing, Geography, Medical, Genetic Carrier Screening
Sponsorship
Cancer Research UK (20861)
Identifiers
External DOI: https://doi.org/10.1136/jmedgenet-2017-105195
This record's URL: https://www.repository.cam.ac.uk/handle/1810/277192
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.